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Abstract: Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor 
(INSTI), which has now been licensed to be used in different countries including the UK. Earlier 
studies have demonstrated that DTG when used with nucleoside backbone in treatment-naïve 
and - experienced patients has been well tolerated and demonstrated virological suppression 
comparable to other INSTIs and superiority against other first-line agents, including efavirenz 
and boosted protease inhibitors. Like other INSTIs, DTG uses separate metabolic pathways 
compared to other antiretrovirals and is a minor substrate for CYP-450. It does not appear to 
have a significant interaction with drugs, which uses the CYP-450 system. Nonetheless, it uses 
renal solute transporters that may potentially inhibit the transport of other drugs and can have 
an effect on the elimination of other drugs. However, the impact of this mechanism appears 
to be very minimal and insignificant clinically. The side effect profiles of DTG are similar to 
raltegravir and have been found to be well tolerated. DTG has a long plasma half-life and is 
suitable for once daily use without the need for a boosting agent. DTG has all the potential to 
be used as a first-line drug in combination with other nucleoside backbones, especially in the 
form of a single tablet in combination with abacavir and lamivudine. The purpose of this review 
article is to present the summary of the available key information about the clinical usefulness 
of DTG in the treatment of HIV infection.
Keywords: dolutegravir, integrase inhibitors, HIV, antiretroviral, treatment
Introduction
The treatment of HIV infection is complex and changes rapidly as advances are made 
in basic science and clinical experience. Understanding of the different stages of viral 
replication and different enzymes used by the virus for their replication have helped to 
identify different agents that can block the function of the enzymes and thereby stop the 
viral replication inside host cells. Various events in the HIV life cycle plus host factors 
have been identified as potential targets for antiretroviral therapy.1,2 The complexity of 
treatment regimens against HIV infection increases further with the rising number of 
available compounds and the growth in new information about their use.
Drugs of five different classes are currently available in the developed world, with 
several others close to release. Inhibitors of HIV reverse transcriptase and of HIV pro-
tease are so far the most developed and most commonly used in clinical practice.3
Newer agents of these classes with better efficacy against the virus and sustained 
activity against viral resistance are in the pipeline of development. Drugs with longer 
half-life that penetrate in to different body compartments with less systemic side 
effects to the host are coming into production.4 Drugs with higher antiviral potency, 
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less side effects, and simpler tablet regimens could improve 
the long-term treatment adherence and longer survival.5
Integrase (IN) has been a target for the drug development 
for sometime.6 Integrase strand transfer inhibitors (INSTIs) 
are one of the five classes of drugs and have demonstrated 
a potent antiviral activity7 and a noninferior efficacy versus 
regimens containing boosted protease inhibitors (PIs) or 
nonnucleoside reverse transcriptase inhibitors (NNRTIs) in 
treatment-naïve patients. INSTI-based regimens are among 
preferred options for first-line therapy for individuals with 
HIV-1 infection. Raltegravir (RAL), elvitegravir (EVG), 
and dolutegravir (DTG) all target the strand transfer step of 
viral DNA integration and are referred to as INSTI drugs. 
These are considered to be first line of treatment options in 
the Europe and the US.6
Dolutegravir – pharmacology, mode 
of action, and pharmacokinetics
DTG is a nitrogen-containing polycyclic compound possess-
ing amide functionality and has two chiral centers, providing 
potential for stereoisomerism.8 It has been derived from the 
patent drug S/GSK1265744, which has one long-acting 
injecting formulation and an oral formulation developed 
as DTG.9
Mode of action
It is well known that integrase inhibitors (INTs, also known 
as integrase strand transfer inhibitors or INSTIs) represent 
a relatively new class of antiretroviral drugs to treat HIV-1 
infection. It inhibits the incorporation of HIV-1 proviral 
DNA into the host cell genome, a step that is vital for viral 
replication. HIV IN is a 32 kDa protein that consists of three 
distinct structural and functional domains: the N-terminal 
domain, the catalytic core domain, and the C-terminal 
domain. It is the highly conserved catalytic triad, known 
as D64D116E152, which is believed to be responsible for 
the enzymatic activity.10
This enzyme catalyzes two vital chemical reactions 
known as 3′ processing and strand transfer. During the first 
of the two steps, IN cleaves two terminal nucleotides from the 
3′ ends of both of the viral DNA strands to expose the invari-
ant CA 3′-OH DNA ends. During the ensuing strand transfer 
step, IN is responsible for catalyzing the integration of viral 
DNA into the chromatin network of the host cell, using the 
freshly exposed 3′-OH ends to attack the phosphodiesterase 
backbone of the host cell DNA.9,10
DTG inhibits the HIV IN by binding to the IN active site 
and blocking the strand transfer step of HIV DNA integration. 
It fits loosely into the binding pocket of the intasome and 
undergoes conformational changes in the pocket structure 
while retaining its binding ability. The ability to make 
adjustment in the binding capacity is potentially favorable 
compared to other INSTIs.11,12
Pharmacokinetics
DTG has favorable pharmacokinetic properties and retains 
plasma concentrations well above the protein-adjusted 90% 
inhibitory concentration (IC90) for HIV-1.11,13
Absorption
DTG is rapidly absorbed following oral administration. The 
median maximum plasma concentration (C
max
) is achieved 
1.5–2.5 hours after oral intake with a mean half-life of 
12–15 hours, rendering feasible for once-daily dosing without 
the need for pharmacological boosting. Bioavailability varies 
with fat content. Song et al14 demonstrated that food intake 
increased DTG exposure and reduced the rate of absorption. 
Healthy subjects received DTG (50 mg) in a single-dose 
crossover study while they were in the fasted state or with 
low-, moderate-, or high-fat meals. The area under the plasma 
concentration–time curve (AUC) from 0 hour to infinity hours 
increased by 33%, 41%, and 66% when administered with 
low-, moderate-, or high-fat meals, respectively, compared 
with the fasting state. However, the increase in DTG expo-
sure is not expected to impact clinical safety and, thus, can 
be taken with or without food and without considering the 
fat content of the food.11,14
Distribution
DTG has got high affinity for plasma proteins, and .99% 
of DTG is bound to plasma proteins, and it is independent 
of the plasma concentration. DTG has good penetration 
to other body compartments and appears to cross the 
blood–brain barrier; however, clinical outcomes have not 
been determined. The apparent volume distribution of 
DTG following oral absorption appears to be around over 
12.5 L, which is comparable to the level seen after intra-
venous administration. This in turn suggests that the drug 
has a very low first-pass metabolism.13 DTG is present in 
other body compartments, including cerebrospinal fluid 
and cervicovaginal fluid. After oral dosing, DTG exposure 
in cervicovaginal fluid was found to be 5%–7% of blood 
plasma exposure compared to around 200% for RAL. In 
semen, the DTG concentration is 6%–7% of blood plasma 
concentration compared to over 400% of ritonavir (RTV). 
The exposure in colorectal tissue is 18%–20% of the blood 
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plasma concentration. It could be due to the fact that DTG 
is highly protein bound, and the amount of free drug pres-
ent may be adequate and comparable to in vitro IC90. DTG 
exposure in cerebrospinal fluid was similar to unbound 
plasma concentrations in blood plasma.11,13
Metabolism
DTG is extensively metabolized in the liver using the Phase II 
metabolism primarily through glucuronidation via UGT1A1, 
while a minor pathway (in Phase I) involves CYP450 3A4 
(CYP3A4) with other minor pathways (Phase II) involving 
UGT1A3 and GT1A9.15
elimination
The terminal half-life is about 14 hours. The apparent oral 
clearance is about 1 L/h. Fifty-three percent of the total oral 
dose of DTG is excreted unchanged in the feces, 32% through 
urine as glucuronide (18%) or alkylated product (3.5%), and 
other organic conjugated products resulting from Phase II 
liver metabolisms. About 1% of unchanged DTG is excreted 
through urine, rendering it relatively safer to use in mild or 
moderate renal impairment.15
Dolutegravir – clinically significant 
drug interactions
DTG has the potential to interact with other medicinal prod-
ucts, including antiretrovirals, but they appear to be clinically 
insignificant in most of the cases.15,16 DTG is metabolized 
by the uridine diphosphate glucuronosyltransferase (UGT) 
enzyme system (Phase II liver metabolism).17 Coadministra-
tion of drugs or medicinal agents that use UGT1A1, UGT1A3, 
and UGT1A9 may alter the blood level of DTG, and some of 
the interactions may have clinical implications (Table 1).11,17
 DTG is a minor substrate for the CYP-P450 system 
(Phase 1 metabolism); however, this could potentially be 
altered when used along with drugs that has major effect on 
CYP-450 system, especially CYP-45 3A4.
Coadministration with drugs using p-glycoprotein and 
breast cancer resistance protein may alter the blood level of 
DTG as well but no clinically significant interaction has been 
reported. DTG uses the organic cation transporter (OCT) 
system in renal tubules and can increase the blood level of 
OCT2-dependent drugs.18 DTG and the pharmacological 
booster cobicistat are the two examples of well-characterized 
Table 1 Key drug interactions of dolutegravir
Interacting drug class Interacting  
drug
Effect on dolutegravir or interacting  
drug concentration
Dose recommendation
Antiretrovirals
 NRTIs TDF No significant effect was observed No change in dose
 NNRTIs eFv Significant reduction in DTG plasma  
concentration
Increase dose of DTG to 50 mg 
twice daily
eTR Significant reduction in DTG plasma  
concentration
Do not administer DTG with eTR 
alone
eTR/DRv/RTv No significant effect was observed DTG and eTR can be used only 
if DRv/r is also included in the 
regimen
 PIs ATv/r Increase in DTG plasma concentration No change in dose
Acid-reducing agents
  Bivalent cations including calcium,  
iron, or zinc supplements, or with 
vitamin-D supplements
Significant reduction in DTG plasma  
concentration, but no interaction  
with PPI
Administer antacids or bivalent 
containing supplements 2 h after or 
6 h before DTG dosing
Antituberculous agents
RIF Significant reduction in DTG plasma  
concentration
Increase the DTG dosing frequency 
to 50 mg twice daily
RBT No significant effect was observed No change in dose
Oral contraceptives
 Ortho-cyclen No significant effect was observed No change in dose
Antihepatitis C virus agents
 PIs BCv No significant effect was observed No change in dose
TRv No significant effect was observed No change in dose
Opioid agonist
Methadone No significant effect was observed No change in dose
Note: Data from the following studies.11,16,18,21,22,25,39,40 
Abbreviations: ATv/r, atazanvir/ritonavir; BCv, boceprevir; DTG, dolutegravir; DRv/RTv, darunavir/ritonavir; eFv, efavirenz; eTR, etravirine; h, hour; NNRTIs, 
nonnucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; RBT, rifabutin; RIF, rifampin; TDF, tenofovir 
disoproxil fumarate; TRv, telaprevir.
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mechanisms of creatinine transporter inhibition in the proxi-
mal tubule. While DTG inhibits mainly the renal transporter 
OCT2 in the basolateral membrane of the proximal tubular 
cell, cobicistat predominantly inhibits the renal transporter 
MATE1 in the luminal membrane,18–20 thereby increasing the 
blood level of creatinine without impairing the true glom-
erular filtration rate. DTG can interact with oral medicinal 
agents, such as antacids containing bivalent cations, and 
the interaction of DTG with bivalent cations21 appears to be 
physical in the form of chelation and, hence, can reduce the 
blood level of DTG (Table 1).
Interaction with specific groups
Antiretrovirals
Similar to RAL, DTG is metabolized primarily by UGT1A1, 
so the number and type of drug–drug interactions (DDIs) are 
expected to be comparable to those seen with RAL.11
Drug interaction between nucleos(t)ide reverse tran-
scriptase inhibitors (NRTIs) and DTG is very minimum and 
clinically insignificant.11 Tenofovir disoproxil fumarate (TDF), 
a NRTI that is primarily eliminated by renal mechanisms, does 
not have any significant interactions with DTG, and these 
two drugs can be taken together without dose adjustment 
(Table 1).
Because NNRTIs display a complicated interaction outline 
and have the potential to induce both the major and minor 
metabolic pathways of DTG, one would expect a reduced DTG 
plasma concentration if these drugs were coadministered.22,23 
When DTG is combined with efavirenz (EFV), there is a 
decrease in AUC, C
max
, trough plasma concentration (C
trough
) 
by 57%, 39%, 75%, respectively, hence, the recommended 
dose of DTG is 50 mg twice daily when coadministered with 
EFV.23
When DTG was combined with etravirine (ETR) in 
healthy volunteers, ETR significantly decreased exposures 
of DTG (AUC and C
trough
 was decreased by 70% and 88%, 
respectively).24 When ETR was combined with a RTV-
boosted PI, the interaction was reversed. But ETR/lopinavir 
(LPV)/RTV treatment had no effect on the DTG plasma 
AUC
0
− and C
max
, whereas the plasma concentration increased 
by 28%. Combination of ETR/darunavir (DRV)/RTV mod-
estly decreased the plasma DTG AUC
0
−, C
max
, and plasma 
concentration by 25%, 12%, and 37%, respectively.25,26 Such 
effects of ETR/LPV/RTV and ETR/DRV/RTV do not appear 
to have any clinical relevance.24 The combination of DTG and 
ETR alone should be avoided, but it may be coadministered 
with ETR without a dose adjustment if DTG and boosted PIs 
is concurrently administered.24
Coadministration of DTG with boosted PIs has been 
studied in randomized trials, and data demonstrate that DTG 
can be coadministered with PIs without dose adjustment. 
DTG was combined with atazanavir (ATV)/RTV and ATV 
in a randomized, open-label, two period’s crossover study 
in healthy adults. The results showed modest, nonclinically 
significant increase in DTG exposure (Table 1). But no dose 
adjustment for DTG was required when coadministered with 
ATV and ATV/RTV, and it was well tolerated.27
Similarly, when DTG was coadministrated with LPV/
RTV there was no clinically significant effect on the steady-
state plasma concentration of DTG and again it showed 
good tolerability (Table 1). Although coadministration of 
DRV/RTV resulted in decreased steady-state plasma DTG 
exposures, the effect is not anticipated to be of clinical 
significance.26
Antacids, calcium, and iron supplements
Polyvalent cations, particularly bivalent cations, including 
calcium, iron, or zinc supplements as well as other cations 
present in antacids, it may chelate DTG and reduce its 
efficacy.21,28 Administering antacids at the same time with 
DTG lowers DTG AUC and minimum plasma concentration 
(C
min
) by 74%. To evade this interaction, DTG should be 
given at least 2 hours before or 6 hours after administering 
polyvalent cations (Table 1). Gastric pH does not seem 
to have any effect on DTG absorption and is not known 
to have any interaction between DTG and proton pump 
inhibitors.21,22
Rifamycin compounds
Rifampin (RIF) is a potent inducer of CYP450 (3A4) and 
UGT1A1. RIF (600 mg) lowers DTG AUC and C
min
 by 54% 
and 72%, respectively; administering RIF with 50 mg of 
DTG twice daily results in DTG levels that are comparable 
to those seen when DTG is dosed at 50 mg once daily with-
out concomitant RIF (Table 1). Therefore, the DTG dosage 
should be increased to 50 mg twice daily for IN-naïve patients 
receiving concomitant RIF.29
Rifabutin (RBT) lowers DTG C
min
 by 30% but does not 
significantly change the AUC or C
max
. Based on these data, 
RBT (300 mg once daily) may be coadministered with 50 mg 
of DTG once daily.29
Direct-acting hepatitis C virus antivirals
Use of boceprevir (BCV) and telaprevir (TRV) with DTG has 
been investigated in healthy volunteers in an open-label study. 
Coadministration of BCV (800 mg every 8 hours) and DTG 
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(50 mg once daily) increased DTG C
max
, AUC, and C
trough
 
by 5%, 7%, and 8%, respectively. This interaction is of no 
clinical significance (Table 1). Similarly, TRV increased DTG 
AUC, C
max
, and C
trough
 by 25%, 19%, and 37%, respectively, 
by the inhibition of CYP3A. When compared to historical 
controls, there was no effect on TRV exposure. Hence, no 
dose adjustment is necessary when DTG is combined with 
direct-acting antivirals.30 DTG has not been found to have any 
significant interaction with grazoprevir and elbasvir, newer 
antivirals for treating hepatitis C virus.31
Other agents
DTG may be given with estrogen/ progestin oral contracep-
tives without dose adjustment and was well tolerated when 
combined with these compounds (Table 1).32
Available data8,11 does not support any possibility for 
DTG to cause clinically significant DDIs with 3-hydroxy-3- 
methyl-glutaryl-co-enzyme A reductase inhibitors such as 
simvastatin, rosuvastatin, and atorvastatin.
Dofetilide is a class III antiarrhythmic agent (available in 
the US in capsules containing 125 µg, 250 µg, and 500 µg 
of dofetilide and not available in Europe and Australia) has 
the potential to interact with DTG.33–35 The use of DTG can 
increase dofetilide level or affect by inhibiting the renal 
OCT2, and thereby increasing the blood level of dofetilide. 
There is a risk of life-threatening arrhythmias when DTG is 
used with dofetilide, and hence, coadministration of these 
two drugs is contraindicated.33,36 Coadministration of DTG 
and metformin was well tolerated. In a study using healthy 
volunteers, coadministration of DTG and metformin was well 
tolerated, but significantly increased metformin plasma expo-
sure, and the effects were DTG dose dependent. Although 
metformin has a wide therapeutic index and alone is not 
associated with hypoglycemia, close monitoring is recom-
mended when coadministering metformin and DTG.37
DTG and prednisone coadministration was well tolerated. 
No dose adjustment is essential for DTG when coadminis-
tered with prednisone.8,38,39 DTG can be taken with or without 
food in treatment-naïve and INSTI-naïve patients. However, 
in treatment-experienced patients in the presence of INSTI 
class resistance, DTG should preferably be taken with food 
to enhance the exposure.14 Methadone use has not been found 
to have any interaction with DTG and dose adjustment for 
methadone or DTG is not recommended.40
Efficacy studies of dolutegravir
DTG use has been studied in HIV treatment-naïve and 
experienced patients and the results are mostly very much 
favorable, standing it relatively ahead of other antiretrovirals 
(Table 2). In SPRING-1,41 a treatment-naïve, Phase IIb ran-
domized dose-ranging multicenter, partially blinded study, 
DTG demonstrated sustained efficacy and a favorable safety 
and tolerability profile. In this study, adults with HIV-1 infec-
tion who were treatment-naïve were randomized to DTG 
10 mg, 25 mg, or 50 mg once daily or 600 mg of EFV once 
daily (control arm) combined with investigator-selected dual 
nucleos(t)ide reverse transcriptase inhibitor (NRTI), back-
bone regimen TDF/emtricitabine (TDF/FTC), or ABC/3TC. 
The primary goal of SPRING-1 was to select a DTG dose 
for Phase III development. A rapid and sustained antiviral 
response was detected across all DTG doses, with 82% of 
all participants who received DTG attaining plasma HIV-1 
RNA ,50 copies/mL through week 96. The safety profile of 
DTG at 96 weeks was favorable, with no dose–response rela-
tionship with adverse events (AEs). Tolerability, in general, 
was also better with DTG in comparison with EFV. There 
was no protocol-defined virological failure in participants 
receiving 50 mg of DTG or resistance mutations to INSTIs 
or NRTIs, and the 50 mg dose was selected for Phase III 
evaluation. DTG demonstrated a sustained efficacy and a 
favorable safety and tolerability profile in a treatment-naïve 
Phase IIb randomized dose-ranging multicenter, partially 
blinded study.
The SINGLE study,42 a head-to-head randomized, double-
blind, Phase III study comprised treatment-naïve adults with 
HIV-1 infection, and the participants were allocated to DTG 
50 mg combined with ABC/3TC once daily or in combination 
therapy with single pill Atripla containing TDF, FTC, EFV 
once daily. At 48 weeks, 88% of the DTG group achieved 
viral load suppression ,50 copies/mL, in comparison to 
81% suppression in the Atripla group. Statistical analysis 
demonstrated that the DTG regimen performed significantly 
better than Atripla (P=0.003) and met the criterion for sta-
tistical superiority. Virological failure was 4% in both arms. 
Results were similar for participants with different baseline 
viral load levels (above or below 100,000 copies/mL). The 
DTG regimen was associated with a significantly higher rise 
in CD4 cells compared to the Atripla group (267 cells/mm3 vs 
208 cells/mm3, respectively, P,0.001). Differences in effi-
cacy were primarily driven by a lower rate of discontinuation 
due to AEs for the DTG plus ABC/3TC arm and were inde-
pendent of baseline viral load. Treatment-related discontinu-
ation was 2% in the DTG arm compared to 10% in the EFV 
arm. The safety profile of the DTG arm in general was more 
favorable when compared to the Atripla arm. No patients in 
the DTG arm developed INSTI or NRTI resistance, whereas 
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one patient on Atripla developed NRTI resistance and four 
patients developed NNRTI resistance.42
At 96 weeks of follow-up, DTG plus ABC/3TC remained 
superior to EFV/TDF/FTC. No major treatment-emergent 
INSTI or NRTI resistance mutations were detected through 
96 weeks with DTG plus ABC/3TC. In this study, 50 mg of 
DTG combined with ABC and 3TC once daily as a single 
pill was superior to single pill Atripla in treatment-naïve 
HIV-1 patients.42
In SPRING-2,43 a 96-week, Phase III, randomized, double-
blind, active-controlled, noninferiority study, treatment-naïve 
adults with HIV-1 infection were randomly assigned (1:1) 
to receive either DTG (50 mg) once daily or RAL (400 mg) 
twice daily. Study drugs were given with coformulated TDF/
FTC or ABC/3TC. The primary endpoint was the proportion 
of participants with HIV-1 RNA ,50 copies/mL at 48 weeks, 
with a 10% noninferiority margin.43
The primary analysis of the SPRING-2 study43 at week 
48 demonstrated that 88% of patients in the DTG arm 
achieved an HIV-1 RNA of ,50 copies/mL compared to 
85% in the RAL arm (adjusted difference 2.5%; 95% CI: 
−2.2 to 7.1). AEs were similar between the two treatment 
groups. There was no evidence of treatment-emergent 
resistance in patients with virological failure on DTG, 
whereas for the patients with virological failure who 
received RAL, one had INSTI treatment-emergent resis-
tance and four had NRTI treatment-emergent resistance. 
DTG has a noninferior efficacy and similar safety profile 
compared to RAL.43 At week 96 analysis in SPRING-2 
study, once-daily DTG was noninferior to the twice-daily 
RAL arm with 81% of patients in the DTG arm and 76% 
of patients in the RAL arm having HIV-1 RNA ,50 copies/
mL (adjusted difference 4.5%, 95% CI: −1.1% to 10.0%) 
and confirmed noninferiority. Median increases in CD4 
cell count from baseline were similar between the groups 
(276 cells/µL for DTG and 264 cells/µL for RAL). No 
study-related serious AEs occurred between week 48 and 
week 96. Ten patients in each group discontinued because 
of AEs. In those who had virological failure, no additional 
resistance to INSTIs or NRTIs was detected since week 
48.44 In this randomized double-blind study, DTG has 
shown a similar efficacy,  tolerability, and safety profile to 
another first-line INSTI.44
The FLAMINGO study45 is a multicenter, open-label, 
Phase IIIb, noninferiority study. Treatment-naïve adults with 
HIV-1 infection were randomly assigned (1:1) to receive 
Table 2 Key efficacy studies of dolutegravir
Naïve studies Participants 
(N)
Design Duration Comparing arm VL ,50 
(%)
Conclusion
SINGLe42 844 Randomized 
1:1
144 wk DTG 50 mg + ABC/3TC  
eFv/FTC/TDF
80% 
72%
DTG superior to eFv 
No treatment-emergent 
resistance in DTG arm
SPRING-243 822 Randomized 
1:1
96 wk DTG 50 mg + two NRTIs 
RAL 400 mg BD + two  
NRTIs
81% 
76%
DTG was noninferior to RAL 
No additional resistance to 
INSTIs or NRTIs since week 48 
in DTG arm
FLAMINGO45 484 Randomized 
1:1
96 wk DTG 50 mg + two NRTIs 
DRv/RTv + two NRTIs
82% 
52%
DTG superior to DRv/RTv 
at 96 wk. Difference most 
pronounced at baseline vL 
.100,000 copies/mL
experienced studies
 SAILING46 715 Randomized 
1:1
48 wk DTG 50 mg + two NRTIs 
RAL 400 mg BD + NRTIs
71% 
64%
Treatment-emergent INSTIs 
resistance (four in DTG arm) vs 
(17 in RAL arm). 
DTG superior to RAL (P=0.03).
 vIKING-348 183 Single-arm  
study
24 wk DTG 50 mg BD + (continuing  
a failing regimen [without  
RAL or evG] 7 days)  
optimized $1 fully active  
drug and DTG continued
69% Reduced response with Q148 + 
$2 resistance mutations 
DTG 50 mg BD-based therapy 
was effective in highly treatment 
experience with INSTI-resistance
 vIKING-449 30 Randomized 
1:1
24 wk DTG 50 mg BD, 7 days on  
failing regimen without RAL  
or evG vs placebo DTG
40% no  
drop
DTG 50 mg BD-based therapy 
was effective in INSTI failing 
regimen
Abbreviations: ABC/3TC, abacavir/lamivudine; DRv/RTv, darunavir/ritonavir; DTG, dolutegravir; eFv, efavirenz; evG, elvitegravir; FTC, emtricitabine; INSTIs, integrase 
strand transfer inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; RAL, raltegravir; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; wk, weeks; vL, viral 
load; BD, twice a day.
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50 mg of DTG once daily or 800 mg of DRV plus 100 mg 
of RTV100 once daily, with investigator-selected TDF/FTC 
or ABC/3TC. No study participants had primary reverse 
transcriptase or protease mutations upon enrolment, and all 
had a viral load above 1,000 copies. The primary endpoint 
was the proportion of patients with HIV-1 RNA concentra-
tion ,50 copies/mL at week 48 with a 12% noninferiority 
margin.
Analysis at week 48 showed 90% of patients in the DTG 
arm and 83% of patients on the DRV plus RTV arm had HIV-1 
RNA of ,50 copies/mL. The adjusted difference of 7.1% 
(95% CI: 0.9%–13.2%) confirmed the superiority of DTG to 
DRV/RTV in antiretroviral-naïve adults (P=0.025). Virological 
failure was similar in both arms, with no treatment-emergent 
resistance recorded in either group. Median CD4 gain was 
similar in both treatment arms. Results, however, among those 
with baseline viral loads .100,000 copies/mL favored DTG. 
There was less discontinuation due to AEs in the DTG arm 
(2%) than for DRV plus RTV (4%) and that may have con-
tributed to the difference in response rates. Once-daily DTG 
was numerically and statistically superior to once-daily DRV 
plus RTV in patients with baseline viral load .100,000 cop-
ies/mL; however, those in the stratum below 100,000 copies 
results were quite comparable. In the FLAMINGO study, DTG 
demonstrated for the second time that it is superior to another 
recommended first-line antiretroviral agent.45
SAILING is a 48-week, Phase III, randomized, double-
blind, active-controlled, noninferiority study involving adults 
who are on failing antiretroviral therapy with ongoing viral 
replication, resistance to two or more classes of antiretroviral 
drugs, and had one to two fully active drugs for background 
therapy.46 They had not been previously exposed to INSTIs. 
Participants received 50 mg of DTG once daily or 400 mg 
of RAL twice daily, with investigator-selected background 
therapy. The primary endpoint was the proportion of patients 
with plasma HIV-1 RNA ,50 copies/mL at week 48, while 
secondary endpoint was the proportion of patients with 
treatment-emergent INSTIs resistance. At week 48 of follow-
up, 71% of patients on DTG had HIV-1 RNA ,50 copies/mL 
versus 64% of patients on RAL (adjusted difference 7.4%, 
95% CI: 0.7–14.2); confirming superiority of DTG against 
RAL (P=0.03). Significantly fewer patients had virological 
failure with treatment- emergent INSTIs resistance on DTG 
(four vs 17 patients; adjusted difference −3.7%, 95% CI: 
−6.1 to −1.2; P=0.003). AE frequencies were similar across 
both groups. Once-daily DTG had greater virological effi-
cacy compared to twice-daily RAL in this treatment-expe-
rienced patient group and was well tolerated. The statistical 
 superiority demonstrated in the DTG arm was driven by 
fewer withdrawals due to lack of efficacy, lower number of 
protocol-defined virological failures, and lower treatment-
emergent resistance.
The safety and efficacy of DTG in treatment-experienced 
subjects with RAL-resistant HIV-1 infection have been 
assessed in the VIKING study.47 In this study, individuals 
received 50 mg of DTG once daily (Cohort I) or 50 mg 
twice daily (Cohort II) while continuing the failing regi-
men (without RAL). After day 10, the background regimen 
was optimized where feasible for Cohort I and at least one 
fully active drug was mandated for Cohort II. The pri-
mary endpoint was the proportion of subjects on day 11 
with $0.7 log10 copies/mL plasma HIV-1 RNA reduction 
below baseline or ,400 copies/mL. Ninety-six percent of 
subjects in Cohort II and 78% of subjects in Cohort I achieved 
the primary end point (ie, a reduction in plasma HIV-1 RNA 
level of $0.7 log10 copies/mL below the baseline value or 
a level of ,400 copies/mL on day 11. Fifty-four percent in 
Cohort II and 41% in Cohort I achieved an HIV-1 RNA level 
of ,400 copies/mL on day 11.47 At week 24, the response 
rate was greater in Cohort II, 75% had a plasma HIV-1 RNA 
level of ,50 copies/mL, in contrast to 41% in Cohort I.47 
The response rates increased in both cohorts as the number 
of fully active agents in the optimized background regimen 
was added.
DTG has also been assessed in antiretroviral-experienced 
patients with RAL- and/or EVG-resistant HIV-1: VIKING-348 
and VIKING-449 study (Table 2). VIKING-3 is a single-arm, 
open-label Phase III study in which INSTIs-experienced 
adults with INSTI-resistant virus received DTG 50 mg 
twice daily while continuing their failing regimen (without 
RAL or EVG and resistance to $2 ART classes other than 
INSTIs). Through day 7, the regimen was optimized with 
one or more fully active drug and DTG continued. Over 
the 8-day monotherapy period, it was obvious that DTG 
demonstrated activity against viruses that have INSTI 
resistance.44 The greatest result was seen in those with a 
history of INSTI resistance but no INSTI resistance muta-
tions at baseline. These patients had a drop in HIV-1 RNA 
of 1.5 log10 copies/mL (P,0.001). At week 24, 74% of 
patients had viral loads below 400 copies/mL and response 
maintained at week 48. Those who had one INSTI mutation 
with Q148 still had a good response, but slightly less than 
those with no mutations. However, the effect was reduced 
when Q148 was paired with $2 INSTI mutations. Safety 
profile on DTG 50 mg twice daily was similar to that with 
DTG 50 mg once daily.45,46 Another study50 has investigated 
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whether DTG-resistant viruses are impaired in their ability 
to acquire further resistance to other agents such as NRTIs 
and NNRTIs as a consequence of their relative inability 
to develop resistance mutations associated with these two 
compounds. In this study,50 the investigators examined the 
ability of DTG-resistant viruses containing either the R263K 
or G118R and/or H51Y mutations to develop further resis-
tance against several reverse transcriptase inhibitors during 
in vitro selection experiments. The investigators were able 
to show that mutations in the R263K and G118R resistance 
pathways delay the emergence of resistance mutations against 
reverse transcriptase inhibitor and suggest that the presence of 
mutations associated with resistance to DTG can impair the 
ability of HIV to acquire further resistance against nevirapine 
and 3TC, a NNRTI, and NRTI, respectively.50 These findings 
may be in line with the conception that R263K may not be 
a deleterious mutation for DTG in contrast to the mutations 
in the RAL/EVG pathways that have the ability to severely 
compromise DTG activity.50
The recently presented data by Granier et al51 from 
pooled analysis of three different naïve studies (SINGLE, 
SPRING-2, and FLAMINGO) have demonstrated the supe-
riority of virological efficacy over comparator in two of the 
three-naïve studies. These pooled analyses suggested no 
evidence of a difference in long-term virological efficacy 
between DTG and third agents or between ABC/3TC and 
TDF/FTC at low or high viral load.
Resistance
DTG has been considered to have a higher genetic barrier 
and minimal cross-resistance compared to other INSTIs.52 
The major mutations that reduced DTG antiviral efficacy in 
vitro were I151L, T66K/L74M, G140/Q148R, G140/G148R, 
and E138K/Q148R. There was an increase in susceptibility 
from 3.5- to 8.4-fold change in susceptibility, but the isolates 
still retain the susceptibility to DTG. The combination of 
mutations at E138K and Q148R results in a tenfold decrease 
in DTG susceptibility compared to a 140–330-fold suscep-
tibility to RAL and 370–390-fold susceptibility to EVG.51 
These data suggest that DTG may still retain antiviral activ-
ity against virus resistant to other two INSTIs. Underwood 
et al has shown that patients failing with RAL with muta-
tions at Y143 or N155 can retain activity with DTG.53 But 
those with Q148 and additional INSTI mutations should 
decrease susceptibility to DTG. There are few other mutations 
like H51Y, which potentially may reduce DTG activity but 
they are very rare and unlikely to appear and further studies 
may delineate more information. The resistance data from the 
available clinical studies have so far shown that multiple IN 
mutations plus a mutation at Q148 are necessary to reduce 
DTG activity.54–56 In the presence of INSTI resistance, the 
dose of DTG should be increased to 50 mg twice daily as has 
been used in VIKING-348 and VIKING-449 studies.
Dolutegravir: adverse effects, safety, 
and tolerability
DTG has revealed a favorable safety profile in Phases II and III 
trials (Table 3). In the SPRING-1 study, there were no dose-
related patterns in type, frequency, or severity of AEs across 
DTG doses, and most events reported in the DTG groups 
were of mild (48%) or moderate (34%) intensity. Only 2% 
of individuals in the SINGLE trial withdrew from the DTG 
arm due to AEs, compared to 10% from the EFV arm.41,42 In 
SPRING-2, DTG and RAL were equally tolerated with only 
ten patients (2%) in each group discontinuing because of AEs. 
No study-related serious AEs occurred between week 48 and 
week 96. Nausea, headache, diarrhea, and sleep disturbances 
were the most common AEs being reported by individuals 
taking DTG (Table 3). Blood levels of DTG in the randomized 
clinical trials56 were not correlated with the presence of the 
most frequent AEs, including diarrhea, nausea, and headache 
or with most clinical laboratory tests of interest.43,57,58 The most 
common laboratory abnormalities reported in the clinical 
trials were increased cholesterol (Figure 1), lipase, biliru-
bin, aspartate transaminase/alanine transaminase, creatine 
phosphokinase, and prothrombin time, as well as decreased 
phosphate and neutrophil count.41,42,56 Patients with underly-
ing hepatitis B or C may be at increased risk of worsening 
or development of transaminase elevations with the use of 
Table 3 Dolutegravir adverse effects grades 2–4 in treatment-
naïve trials
Side effects Range (%) Comments
Gastrointestinal 2–17 Diarrhea and nausea were the most 
common GI side effects, mainly mild-
to-moderate in severity
Headache 1–15 Mainly mild in nature
Insomnia 1–4 were typically mild in intensity
Rash 1 Were significantly low in most of the 
studies (generalized macular rash, 
maculopapular rash, pruritic rash)
Liver abnormality 2–3 Alternative causes for raised ALT 
identified in few patients. Very few 
patients had DTG-associated DILI 
with hypersensitivity reaction
Nasopharyngitis ,1 Mild in nature
Note: Data from the following studies.41–45
Abbreviations: DTG, dolutegravir; DILI, drug-induced liver injury; GI, gastro-
intestinal; ALT, alanine transaminase. 
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DTG. In some cases, the elevations in transaminases were 
consistent with immune reconstitution syndrome or hepatitis 
B reactivation, particularly in the setting where antihepatitis 
therapy was withdrawn. The AEs did not appear to be related 
to plasma DTG exposure.
 Overall, DTG is well tolerated, with headache 
and insomnia being the most frequently reported AEs. 
A systematic review by Patel et al59 has demonstrated that 
DTG use was associated with a relatively lower risk of 
AEs and less risk of withdrawal from studies due to AEs 
compared to other antiretrovirals including EFV, boosted 
PIs, but no difference compared to RAL and rilpivirine 
use (Table 3).
Hypersensitivity reactions have been reported in ,1% of 
subjects receiving DTG in Phase III randomized controlled 
clinical trials.41,42 More over DTG when used in a combination 
product with ABC and 3TC marketed as triumeq has the 
potential to have hypersensitivity reactions as seen in ABC 
use alone. Clinically, it is unlikely to be differentiated whether 
the reaction is due to ABC or DTG.
effect of dolutegravir on lipids
DTG appears to be lipid neutral. In comparative analysis 
from the SINGLE, SPRING-2, and FLAMINGO stud-
ies, DTG demonstrated a generally neutral effect on 
serum lipid changes irrespective of nucleoside backbone 
(Figures 1–4).59,60 The total cholesterol/high-density lipo-
protein ratio remained similar in all the groups (Figure 5). 
This is comparable to the similar effect seen with other 
INSTIs, namely, RAL. In a systematic review, Patel et al59 
showed that DTG use was associated with lower rise of 
total cholesterol, low-density lipoprotein cholesterol, and 
triglyceride compared to EFV and boosted PIs, including 
ATV, DRV, and LPV.60
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Figure 1 Mean TC changes from baseline at 48 weeks.
Abbreviations: DRv/RTv, darunavir/ritonavir; DTG, dolutegravir; eFv, efavirenz; RAL, raltegravir; TC, total cholesterol.
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Abbreviations: DRv/RTv, darunavir/ritonavir; DTG, dolutegravir; eFv, efavirenz; LDL-C, low-density lipoprotein cholesterol; RAL, raltegravir.
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effect on bone health
DTG like other INSTIs appears to have less effect on bone 
health. In SINGLE study after 48 weeks of follow-up, bone 
markers were increased in both groups, but the increases were 
significantly higher in the Atripla group. Vitamin-D levels 
are decreased in both the arms, but the differences were not 
different.61 The BMD changes as demonstrated by DEXA 
scan did not reveal any difference in DTG use.61 Recently 
presented data from the study after 144 weeks of follow-up 
have shown an increased turnover of bone markers in the 
Atripla arm compared to the DTG arm. Vitamin-D levels 
were similar in both groups.62
Use in special population
DTG so far appeared to be safe and well tolerated in both 
treatment-naïve and treatment-experienced patients. In the 
absence of more robust information, caution should be taken 
in specific populations (Table 4).
Dolutegravir – patient perspectives 
quality of life, patient satisfaction 
and acceptability, adherence
There are important factors to think of when deciding 
whether a given regimen should be considered a “recom-
mended” option for a first-line therapy such as efficacy, 
tolerability, and convenience of taking the drug, which all 
play important roles.3 This also includes, drug–drug and 
drug–food interactions, as well as baseline patient-specific 
factors such as CD4+ cell count,3 plasma HIV-1 RNA level, 
child-bearing potential (in women), and a range of comor-
bidities, including viral hepatitis coinfection.63 All three 
INSTIs are now included within the treatment guidelines for 
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Figure 3 Mean TG changes from baseline at 48 weeks.
Abbreviations: DRv/RTv, darunavir/ritonavir; DTG, dolutegravir; eFv, efavirenz; RAL, raltegravir; TG, triglyceride.
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the adult HIV patients.3 In randomized controlled  studies, 
DTG has shown superiority over two other commonly used 
third agents, EFV and boosted DRV. DTG has a novel resis-
tance profile, it has shown activity against HIV-1 isolates 
with INSTI-resistant strains with no emergent resistance 
to date with first-line DTG failure. DTG is metabolized by 
UGT1A, with minimal contribution from cytochrome P450 
(3A4 isoform) and limiting DDI.11 DTG has a prolonged 
intracellular half-life; thus, once-daily dosing without the 
need for pharmacological booster is acceptable if taken 
with or without food.8,11 INSTIs are potent agents, well 
tolerated with favorable metabolic profiles and few DDIs 
(RAL, DTG). Despite the rates of transmitted (baseline) drug 
resistance to INSTIs alleged to be low, resistant phenotypes 
have been reported for both RAL and EVG.64 Certain muta-
tions confer cross-resistance between both agents (RAL and 
EVG), but DTG has a better resistance profile and so far 
appears to have relatively higher genetic barriers.46,65
Pill burden, twice daily regimen, relation of food and 
content of food, taking pills at particular time of the day 
had all been factors with antiretrovirals.66,67 DTG has the 
potential to overcome all these barriers and can be taken 
once daily as a single pill at any time of the day without 
the need for food. This has the potential advantage of giv-
ing patients the liberty to take medications at their choice, 
not compromising with their daily life promising a better 
quality of life. Moreover, HIV patients are living longer 
and when polypharmacy is common in patients in aged 
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Figure 5 TC:HDL ratio changes from baseline at 48 weeks.
Abbreviations: DRv/RTv, darunavir/ritonavir; DTG, dolutegravir; eFv, efavirenz; RAL, raltegravir; TC:HDL, total cholesterol:high-density lipoprotein.
Table 4 Use of dolutegravir in special population
Conditions Findings Comment
Pregnancy Categorized as pregnancy category B. No adequate and well-controlled studies in  
pregnant women because animal reproduction studies are not always predictive  
of human response.8,72
To be used with caution.
Nursing mother In animal studies DTG was present in rat milk, human data are not available.72 No clear evidence.
Pediatric Safety and efficacy of use of DTG has not been established in pediatric patients  
younger than 12 years and weighing ,40 kg.
No clear evidence.
elderly The data of safety in patients aged over 65 years is very limited. To be used with caution.
Renal The plasma concentration of DTG was found to be decreased in subjects with  
severe renal impairment compared to those in the healthy controls; however, no  
dose adjustment was necessary where renal impairment was mild-to-moderate.73,74 
No data on renal dialysis patients.
Caution in severe renal 
impairment.
Hepatic There have not been any differences between subjects with moderate hepatic  
impairment and hepatic subjects.63,75,76
No dose adjustment in mild or 
moderate hepatic impairment.
Hepatitis B and C coinfection DTG can be safely used with boceprevir and telaprevir.30,63 No dose adjustment.
Abbreviation: DTG, dolutegravir.
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population,68 less pill burden and minimal drug interaction 
appears to be a distinct advantage of DTG compared to 
others.69 The debate of using DTG with ABC in patients 
with high-risk cardiovascular disease remains and that 
has to be dealt with on an individual patient level.70,71 
INSTI-based regimens may be appropriate for many (if 
not most) treatment-naïve patients and DTG represents a 
new option for INSTIs-experienced patients.
Conclusion
DTG is an INSTI that maintains a high plasma level and 
supports a once-daily dosing regimen without the need for a 
pharmacokinetic boosting agent. DTG in combination with 
ABC and 3TC has developed a single-tablet regimen for 
the treatment of HIV infection. Such treatment could have 
the potential to be advantageous over the other combination 
antiretroviral agents available as a single tablet. As there is 
very minimal effect on Phase I liver metabolism involving 
CYP-pathway, it is unlikely to interact with other antiret-
roviral agents and a very minimum interaction with other 
commonly used medicinal agents.
Although there is potential for the interaction at renal 
tubular level involving OCTP, the clinical significance so 
far appeared to be very minimum. DTG, the third INSTI, 
appears comparable to or better than guideline-approved 
first-line antiretroviral agents with potent antiviral activity. 
DTG remains the agent with good tolerability and better 
patient safety. It has multiple clearance pathways and little 
clinically significant pharmacokinetic variability, and it has 
also a predictable exposure–response relationship. DTG 
has the advantage of being a once-daily tablet, with a small 
milligram dose and tablet size. Although the size of the 
combination tablet containing DTG, ABC, and 3TC named 
as triumeq is not smaller than the available single-pill regi-
men, it has been well tolerated in all the randomized control 
trials and appeared to be safe and effective. DTG has the 
potential to become the first-line antiretroviral agent, with 
a strong prospect of offering a good quality of life for the 
patients.
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